摘要
目的观察野鸢尾黄素对人脑胶质瘤LN229细胞的增殖、迁移和侵袭能力,以及基质金属蛋白酶-2(MMP-2)表达的影响。方法将细胞分为3组,分别为空白对照组和低、高剂量实验组。空白对照组不加任何药物;低、高剂量实验组分别加入40和80μmol·L-1野鸢尾黄素。用免疫荧光实验检测细胞增殖能力,用Tranwell小室实验检测细胞的迁移和侵袭能力,用蛋白质印迹法检测MMP-2蛋白的表达水平。结果干预48 h后,空白对照组和低、高剂量实验组的细胞增殖率分别为(38.07±2.53)%,(23.90±1.10)%和(12.00±2.65)%,迁移细胞数量分别为(683.33±110.15),(322.00±72.19)和(132.33±18.23)个,侵袭细胞数量分别为(715.33±109.70),(300.00±60.67)和(135.00±30.64)个,MMP-2蛋白相对表达量分别为0.95±0.05,0.77±0.06和0.27±0.06。低、高剂量实验组的上述指标与空白对照组相比,差异均有统计学意义(P <0.05或P <0.01或P <0.001)。结论野鸢尾黄素可能通过抑制MMP-2的表达,从而抑制LN229细胞的增殖、迁移及侵袭。
Objective To observe the effects of irigenin on the viability,proliferation,migration and invasion of human glioma LN229 cells and the expression of matrix metalloproteinase-2(MMP-2).Methods LN229 cells were divided into three groups:blank control group,experimental-L and-H groups.The blank control group did not add any drugs,while the experimental-L and-H groups were added with40 and 80 μmol·L-1 irigenin,respectively.Immunofluorescence assay was used to detect cell proliferation,transwell chamber assay was used to detect cell migration and invasion,and Western Blot was used to detect the expression of MMP-2 protein.Results After treatment 48 h,the cell proliferation rates of blank control group,experimental-L and-H groups were(38.07±2.53) %,(23.90±1.10) % and(12.00±2.65) %,the migration numbers was 683.33±110.15,322.00±72.19 and 132.33±18.23,the invasion number was715.33±109.70,300.00±60.67 and 135.00±30.64,the relative expressions of MMP-2 protein were 0.95±0.05,0.77±0.06 and0.27±0.06,respectively.And the differences were statistically significant between blank control group and experimental-L and-H groups(P <0.05 or P <0.01 or P <0.001).Conclusion Irigenin may inhibit the proliferation,migration and invasion of LN229 cells by inhibiting the expression of MMP-2.
作者
周扬
朱冰影
周希禛
朱缨
沈敏
钟其新
曾峰
ZHOU Yang;ZHU Bing-ying;ZHOU Xi-zhen;ZHU Ying;SHEN Min;ZHONG Qi-xin;ZENG Feng(Suzhou Key Laboratory of Medical Biotechnology,Pharmacy Department,Suzhou Vocational Health College,Suzhou 215009,Jiangsu Province,China;Oncology Department of Traditional Chinese Medicine,Hangzhou First People's Hospital Affiliated to Zhejiang University Medical College,Hangzhou 310006,Zhejiang Province,China;Department of Geriatrics,Shenzhen Hospital,Guangzhou University of Chinese Medicine,Shenzhen 518034,Guangdong Province,China;Artemisinin Research Center,Guangzhou University of Chinese Medicine,Guangzhou 510445,Guangdong Province,China;Scientific Research Office,The First Affiliated Hospital,Guangzhou University of Chinese Medicine/The First Clinical Medical School,Guangzhou University of Chinese Medicine,Guangzhou 510405,Guangdong Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2021年第19期2618-2621,共4页
The Chinese Journal of Clinical Pharmacology
基金
国家自然科学基金青年基金资助项目(31901002)
江苏省卫生健康委医学科研基金资助项目(Z2019051)
苏州市科技局民生科技基金资助项目(SYSD2018072)
福田区卫生公益科研基金资助项目(FTWS2019024
FTWS2020050)
苏州卫生职业技术学院青年科技专项基金资助项目(SZWZY201711)。